Abstract
DARS, encoding for aspartyl-tRNA synthetase, is implicated in the pathogenesis of various cancers, including renal cell carcinoma, glioblastoma, colon cancer, and gastric cancer. Its role in BCR/ABL1-negative myeloproliferative neoplasms (MPNs), however, remains unexplored. This study aimed to elucidate the expression of DARS in patients with MPNs (PV 23, ET 19, PMF 16) through immunohistochemical analysis and to examine the profiles of circulating immune cells and cytokines using flow cytometry. Our findings indicate a significant overexpression of DARS in all MPNs subtypes at the protein level compared to controls (P < 0.05). Notably, elevated DARS expression was linked to splenomegaly in MPNs patients. The expression of DARS showed a negative correlation with CD4+ T cells (R = - 0.451, P = 0.0004) and CD4+ T/CD8+ T cell ratio (R = - 0.3758, P = 0.0040), as well as with CD68+ tumor-associated macrophages (R = 0.4037, P = 0.0017). Conversely, it was positively correlated with IL-2 (R = 0.5419, P < 0.001), IL-5 (R = 0.3161, P = 0.0166), IL-6 (R = 0.2992, P = 0.0238), and IFN-γ (R = 0.3873, P = 0.0029). These findings underscore a significant association between DARS expression in MPNs patients and specific clinical characteristics, as well as immune cell composition. Further investigation into the interplay between DARS and the immune microenvironment in MPNs could shed light on the underlying mechanisms of MPNs pathogenesis and immune dysregulation.
Introduction
Myeloproliferative neoplasms (MPNs)—including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF)—are clonal stem cell disorders primarily driven by mutations such as $JAK2V617F$. While the genetic drivers are well-documented, clinical management is often complicated by drug resistance and systemic inflammation.
Recent research has turned toward immunometabolism to understand how cancer cells reprogram their metabolic pathways to fuel growth and evade the immune system. Aminoacyl-tRNA synthetases (ARSs), such as DARS (aspartyl-tRNA synthetase), have been identified as dysregulated in several solid tumors. However, their role in $BCR/ABL1$-negative MPNs has remained largely unexplored. This study investigates whether DARS expression correlates with clinical burden and immune dysfunction in MPN patients.
Methods
The study profiled 58 MPN patients (23 ET, 19 PV, 16 PMF) and 12 controls with benign hematological disorders.
- Immunohistochemistry (IHC): Bone marrow biopsy specimens were analyzed to quantify DARS protein levels and CD68+ macrophage infiltration using the Immunoreactive Score (IRS).
- Flow Cytometry: Peripheral blood was analyzed to determine the frequency of lymphocyte subsets, including CD4+ and CD8+ T cells.
- Cytokine Assay: A multiplex kit measured 12 plasma cytokines to map the inflammatory landscape.
- Statistical Analysis: Spearman correlation and t-tests were employed to link DARS expression with clinical symptoms and immune profiles.
Results
Significant Overexpression of DARS
DARS protein levels were significantly elevated in all MPN subtypes compared to the control group ($P < 0.001$). The Immunoreactive Score (IRS) demonstrated that high DARS expression is a consistent feature across ET, PV, and PMF, suggesting its role as a potential metabolic marker for these neoplasms.
Clinical Correlation and Disease Load
High DARS expression was found to scale with disease severity. In ET and PMF subgroups, elevated DARS was strongly associated with splenomegaly ($P = 0.006$ and $P = 0.034$, respectively) and increased lactate dehydrogenase (LDH) levels, indicating higher cell turnover and disease burden.
Immune Microenvironment and CD4+ T Cell Depletion
A critical finding of this study is the negative correlation between DARS expression and the frequency of CD4+ T cells ($R = -0.451, P = 0.0004$). Patients categorized in the "High DARS" group exhibited significantly lower percentages of CD4+ T cells compared to the "Low DARS" group, suggesting that DARS-overexpressing clones may contribute to an immunosuppressive environment.
Furthermore, DARS expression positively correlated with CD68+ tumor-associated macrophages (TAMs) ($R = 0.4037, P = 0.0017$) and pro-inflammatory cytokines such as IL-6 and IFN-$\gamma$. This suggests a dual role for DARS in promoting both immune evasion and the "cytokine storm" characteristic of MPN progression.
Discussion
This study identifies DARS as a significant player in the landscape of $BCR/ABL1$-negative MPNs. The correlation between DARS levels, clinical symptoms like splenomegaly, and the depletion of CD4+ T cells highlights a potential immune-metabolic axis that drives disease progression.
While these correlations are robust, the study is limited by its sample size and the lack of direct mechanistic evidence. Future research utilizing CRISPR or RNAi knockdown in MPN cell lines is necessary to determine if DARS directly causes immune suppression. Nonetheless, DARS emerges as a promising biomarker for identifying patients at risk for high disease burden and immune failure, potentially serving as a future therapeutic target.
Summary updated